V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016634 | 160013379 | 0 | 98 | Palliative (P) | 2017-10-15 | 2018-08-13 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101340491 |
| 160016636 | 160013380 | 1.72 | 40.4 | Palliative (P) | 2020-06-26 | 2020-11-09 | PEMBROLIZUMAB | 02 | null | GEMCITABINE | 100921383 |
| 160016640 | 160013381 | 1.64 | 60.7 | Palliative (P) | 2017-10-20 | 2017-10-20 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | N | NB HRNBL-1 BUMEL MAT | 100225927 |
| 160016641 | 160013382 | 1.81 | 88.7 | Palliative (P) | 2017-04-03 | 2017-04-05 | Ifosfamide 3g/m2 5 day | 01 | N | CARBOPLATIN + VINORELBINE | 100119618 |
| 160016643 | 160013383 | 1.55 | 46.2 | null | 2018-04-16 | 2018-04-17 | Doxorubicin + Ifosfamide | 02 | null | CAPECITABINE | 101340545 |
| 160016646 | 160013384 | 1.69 | 19.5 | null | 2019-10-23 | 2019-11-26 | NB HRNBL-1 COJEC Ind COURSE B | 02 | null | GEMCITABINE | 100730705 |
| 160016655 | 160013385 | 1.72 | 70.6 | Neo-adjuvant (N) | 2019-09-02 | 2019-10-06 | Niraparib | 02 | N | VINCRISTINE | 100203446 |
| 160016657 | 160013386 | 0 | 99.4 | Palliative (P) | 2019-05-28 | 2019-07-06 | CARBOPLATIN + GEMCITABINE | N | N | RUCAPARIB | 101570378 |
| 160016660 | 160013387 | 1.68 | 70.05 | Adjuvant (A) | 2022-02-10 | 2022-02-11 | STS Non-Rhabdo EpSSG 2005 Ifos | 01 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101339215 |
| 160016662 | 160013388 | 1.62 | 78.5 | Curative (C) | 2017-05-18 | 2017-11-10 | Palbociclib | 02 | null | CYCLOPHOSPHAMIDE | 101470002 |
| 160016669 | 160013390 | 1.6 | 102 | null | 2018-01-16 | 2018-02-26 | GEMCITABINE | 02 | null | NEMO TRIAL | 101742044 |
| 160016671 | 160013391 | 0 | 63 | Palliative (P) | 2019-09-08 | 2019-10-09 | Etoposide oral | 02 | N | IRINOTECAN + VINCRISTINE | 100844767 |
| 160016675 | 160013392 | null | 69 | Palliative (P) | 2020-04-09 | 2020-04-11 | Dinutuximab Beta | N | N | PEMBROLIZUMAB | 100872158 |
| 160016678 | 160013393 | null | 40.7 | Palliative (P) | 2021-06-19 | 2021-09-04 | null | 02 | N | EW EUROEWING 2012 ARM B IE | 100848983 |
| 160016681 | 160013394 | 1.69 | 55.1 | null | 2016-03-29 | 2016-06-29 | null | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100640432 |
| 160016684 | 160013395 | 1.63 | 17.1 | Curative (C) | 2017-04-06 | 2017-10-08 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | CAPECITABINE + MITOMYCIN | 101698013 |
| 160016686 | 160013396 | 1.59 | 109 | Adjuvant (A) | 2017-05-31 | 2017-06-07 | IVA | 01 | N | RMS 2005 TRIAL | 100022000 |
| 160016690 | 160013397 | 1.42 | 58.6 | Curative (C) | 2019-07-15 | 2019-08-12 | Olaratumab | N | Y | EW EUROEWING 2012 ARM B IE | 101122849 |
| 160016692 | 160013398 | 0 | 18.5 | Curative (C) | 2020-07-27 | 2020-07-27 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | NOT MATCHED | 100161840 |
| 160016695 | 160013399 | 0 | 65 | Neo-adjuvant (N) | 2018-03-31 | 2018-06-01 | STS Rhabdo VIT0910 Vinc Irinotecan | N | N | STS RHABDOMYOSARCOMA RELAPSE IRINOTECAN/ TEMOZOLOMIDE/ VINCRISTINE | 100398565 |
| 160016698 | 160013400 | 1.63 | 40.4 | null | 2019-10-31 | 2019-11-04 | Carboplatin + Doxorubicin | 01 | null | CARBOPLATIN + ETOPOSIDE | 100699335 |
| 160016701 | 160013401 | 1.47 | 114.6 | Palliative (P) | null | 2017-07-12 | GC Int Guide Excranial GrmCell VeIP | 02 | N | CREATE TRIAL | 100137788 |
| 160016703 | 160013402 | 1.88 | 74.3 | null | 2019-04-18 | 2019-08-14 | NB HRNBL | 01 | null | RUCAPARIB | 101594163 |
| 160016706 | 160013403 | 0 | 51.4 | Curative (C) | 2019-02-28 | 2019-07-27 | ECX | Y | N | DOXORUBICIN + IFOSFAMIDE | 100928396 |
| 160016707 | 160013404 | null | 55.5 | Curative (C) | 2019-05-27 | 2019-05-28 | CONFIRM TRIAL | 02 | N | STS NON-RHABDO EPSSG 2005 IFOS | 100086975 |
| 160016711 | 160013406 | 1.58 | 4.6 | null | 2017-07-01 | 2017-10-06 | Cisplatin + Etoposide po | 01 | null | EW EUROEWING 2012 ARM B IE | 100851842 |
| 160016712 | 160013407 | 0 | 61.9 | Disease modification (D) | 2016-10-24 | 2016-11-20 | Cyclophosphamide + Vincristine | Y | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 100683768 |
| 160016714 | 160013408 | 1.77 | 107 | Palliative (P) | 2018-10-08 | 2018-10-09 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100389479 |
| 160016718 | 160013409 | 1.8 | 14 | Palliative (P) | 2015-06-13 | 2016-12-28 | PROMISE-MESO TRIAL | 02 | N | NOT MATCHED | 100521302 |
| 160016720 | 160013410 | 1.61 | 79.6 | null | 2017-09-23 | 2018-06-26 | VAC | 02 | null | NB HRNBL-1 BUMEL MAT | 100139404 |
| 160016721 | 160013411 | 1.14 | 10.2 | null | 2018-10-24 | 2018-11-28 | IVA | 02 | null | EW EUROEWING 2012 ARM B IE | 100121389 |
| 160016722 | 160013412 | 1.68 | 65 | Palliative (P) | 2019-09-09 | 2019-09-09 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | NOT MATCHED | 101781879 |
| 160016727 | 160013413 | 1.65 | 86.8 | null | 2019-02-18 | 2019-06-30 | Cyclophosphamide oral | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100434959 |
| 160016728 | 160013414 | 1.61 | 37 | null | 2019-09-25 | 2019-10-09 | GEMCITABINE | 02 | null | NB HRNBL-1 COJEC IND COURSE A | 101189672 |
| 160016730 | 160013415 | null | 71.5 | null | null | 2018-09-18 | Dinutuximab Beta | Y | null | CISPLATIN + GEMCITABINE | 100155044 |
| 160016731 | 160013416 | 1.78 | 9.9 | null | 2016-07-17 | 2016-07-20 | Ifosfamide | 02 | null | TRIAL | 101509788 |
| 160016732 | 160013417 | 0 | 106.6 | 03 | 2019-04-18 | 2019-04-18 | Niraparib | null | N | TRIAL | 100892266 |
| 160016734 | 160013418 | 1.82 | 49.85 | Palliative (P) | 2018-02-08 | 2018-02-22 | Cyclophosphamide oral | null | Y | STS RHABDO RMS 2005 VIN CYCLO | 100068510 |
| 160016743 | 160013421 | 1.8 | 92.5 | Curative (C) | 2019-05-20 | 2019-05-27 | Docetaxel | 2 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101022985 |
| 160016744 | 160013422 | 1.65 | 58.2 | null | 2018-10-23 | 2018-10-24 | VAI (Ifos 3g/m2) | 02 | null | ICON8B TRIAL | 101256662 |
| 160016745 | 160013423 | 1.52 | 98 | Neo-adjuvant (N) | 2020-01-14 | 2020-01-17 | NB Low/Intermed risk guidelines CADO | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 101560703 |
| 160016747 | 160013424 | 1.62 | 84.4 | Disease modification (D) | 2017-01-16 | 2017-02-12 | CEDIRANIB | Y | N | DACARBAZINE + GEMCITABINE | 100820783 |
| 160016749 | 160013425 | 0 | 0 | Palliative (P) | 2018-12-30 | 2018-12-31 | EW EuroEwing 2012 Arm A VIDE | 02 | N | NOT MATCHED | 100080250 |
| 160016750 | 160013426 | 0 | 105 | Curative (C) | 2017-06-14 | 2017-06-26 | Doxorubicin + Ifosfamide | 02 | null | CYCLOPHOSPHAMIDE | 100610827 |
| 160016752 | 160013427 | null | 83.5 | null | 2017-02-20 | 2018-02-04 | EW Rel rEECur Irinotecan/Temozolomide | null | null | CYCLOPHOSPHAMIDE | 101614131 |
| 160016758 | 160013429 | 1.7 | 77.4 | Curative (C) | 2015-04-14 | 2015-04-14 | Palbociclib | 02 | N | EW REL REECUR GEMCITABINE/DOCETAXEL | 100457650 |
| 160016764 | 160013430 | 1.7 | 71.8 | Curative (C) | 2021-04-30 | 2021-05-01 | EW EuroEwing 2012 Arm A VAI | 01 | N | GEMCITABINE | 100113762 |
| 160016774 | 160013431 | 0 | 68.4 | Palliative (P) | 2019-11-06 | 2019-12-12 | Fulvestrant + Ribociclib | 01 | N | DACARBAZINE + GEMCITABINE | 100382489 |
| 160016777 | 160013432 | 1.63 | 135 | null | 2020-03-09 | 2020-03-19 | CONFIRM TRIAL | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101479368 |
| 160016779 | 160013433 | 1.79 | 13.8 | Palliative (P) | 2018-02-12 | 2018-02-14 | Rucaparib | N | N | RUCAPARIB | 100909788 |